Knyga 2008 09_2 be EndNote.indd - Saulius Äaplinskas
Knyga 2008 09_2 be EndNote.indd - Saulius Äaplinskas
Knyga 2008 09_2 be EndNote.indd - Saulius Äaplinskas
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Atsako į AIDS ir narkomaniją kontroversijos<br />
Literatūros sąrašas<br />
1 Čaplinskas S, Liutkevičienė I. AIDS: geriau žinoti. Vilnius: Tyto alba,<br />
20<strong>09</strong>: 150.<br />
2 Čaplinskas S. ŽIV/AIDS profilaktikos programų efektyvumas. Lietuvos<br />
<strong>be</strong>ndrosios praktikos gydytojas 2004; 8(3): 2<strong>09</strong>-14.<br />
3 Blower SM, McLean AR. Prophylactic vaccines, risk <strong>be</strong>havior change,<br />
and the probability of eradicating HIV in San Francisco. Science 1994;<br />
265(5177): 1451–54.<br />
4 Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis<br />
for HIV prevention in men who have sex with men. N Engl J Med 2011;<br />
363: 2587–99.<br />
5 Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness<br />
and safety of tenofovir gel, an antiretroviral microbicide, for the<br />
prevention of HIV infection in women. Science. 2010; 329 : 1168–74.<br />
6 Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with<br />
ALVAC and AIDSVAX to prevent HIV -1 infection in Thailand. N Engl J<br />
Med 20<strong>09</strong>; 361: 22<strong>09</strong>–20.<br />
7 Likatavičius G, Čaplinskas S, Rakickienė J. HIV/AIDS epidemiology in<br />
Lithuania. Acta medica Lituanica. 2001; suppl.6: 17-24.<br />
8 Hamers FF, Downs AM. HIV in central and eastern Europe. Lancet<br />
2003; 361(9362):1035-44.<br />
9 Čaplinskienė I. Ar gali ŽIV infekcija iš didelės rizikos tikslinių grupių<br />
plisti į <strong>be</strong>ndrąją populiaciją Lietuvoje. Medinfo 2004; 3: 37-9.<br />
10 Čaplinskas S. Moksliškai pagrįsti priklausomumo nuo narkotikų gydymo<br />
modeliai. Nervų ir psichikos ligos: specializuotas „Gydymo meno”<br />
priedas. 2004; 1 (13): 35.<br />
11 Čaplinskas S. ŽIV plitimo tarp narkotikų vartotojų prevencijos principai.<br />
Gydymo menas. ISSN 1392-527X. 2003; 9: 24-5.<br />
12 Čaplinskas S. Narkotikų kontrolė: pragmatiška politika ir humanistinės<br />
nuostatos. Acta medica Lituanica. 2001; suppl.6: 37-41.<br />
13 Södergard B, Halvarsson M, Tully MP, et al. Adherence to treatment in<br />
Swedish HIV-infected patients. J Clin Pharm Ther 2006; 31(6):605-16.<br />
14 Hilton BA, Thompson R, Moore-Dempsey L, et al. Harm reduction<br />
theories and strategies for control of human immunodeficiency virus:<br />
a review of the literature. Journal of Advanced Nursing 2001; 33(3):<br />
357-70.<br />
15 Report on the global HIV/AIDS epidemic. Geneva: UNAIDS 2002.<br />
16 UNAIDS terminology guidelines, <strong>2008</strong>.<br />
17 Mazus AI, Leven II, Vinogradova OV, Zelenev VV, Makarenko OV. The<br />
sociological monitoring as a tool to evaluate preventive activities.<br />
Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med 20<strong>09</strong>; 3:32-4.<br />
18 Conference Summary Report on the 6th IAS Conference on HIV<br />
Pathogenesis, Treatment and Prevention (IAS 2011).17-20 July 2011.<br />
Rome, Italy.<br />
19 Nuo patirties perėmėjo iki geros praktikos skleidėjo – tai 20 metų AIDS<br />
centro veiklos bagažas: [pokalbis su Lietuvos AIDS centro direktoriumi<br />
Sauliumi Čaplinsku]. – Nuotr. // Lietuvos medicinos kronika. – 20<strong>09</strong>,<br />
liepos 1, p. 7, 8.<br />
20 25-eri metai su AIDS: [pokalbis su Lietuvos AIDS centro direktoriumi<br />
Sauliumi Čaplinsku]. – Nuotr. // Lietuvos medicinos kronika. – 20<strong>09</strong>,<br />
liepos 15, p. 5, 8.<br />
21 Caplinskiene I, Caplinskas S. Antiretroviral therapy (ART) coverage<br />
and expenditures for ART in Lithuania. Abstract book „HIV in European<br />
region – unity and diversity”, Tallinn, May 25-28, 2011; 168.<br />
22 Lee CK, Lee HK, Loh TP, et al. An in-house HIV genotyping assay for the<br />
detection of drug resistance mutations in Southeast Asian patients<br />
infected with HIV-1. J Med Virol 2012; 84(3):394-401.<br />
23 Kolupajeva T, Aldins P, Guseva L, Dusacka D, Sondore V, Viksna L,<br />
Rozentale B. HIV drug resistance tendencies in Latvia. Cent Eur J<br />
Public Health <strong>2008</strong>; 16(3):138-40.<br />
24 Rolleston Report. Departmental Commission on Morphine and<br />
Heroin Addiction, United Kingdom. 1926. Prieiga per internetą: http://<br />
www.drugtext.org/Table/Rolleston-Report/.<br />
25 Waal H. Risk reduction as a component of a comprehensive, multidisciplinary<br />
approach to drug abuse problems. Discussion paper.<br />
P-PG/MIN/CONF 2000; 3. Prieiga per internetą: https://wcd.coe.int/<br />
ViewDoc.jspid=1302287&Site=COE<br />
26 Satel SL. What should we expect from drug abusers Psychiatric<br />
Services. 1999;50(7):861.<br />
27 Califano JA. Should drugs <strong>be</strong> decriminalised No. BMJ 2007;<br />
335(7627):967.<br />
28 Collins L. Nepasisekęs Olandų eksperimentas su narkotikais. Vilnius<br />
1999; 8.<br />
29 First Conference, European Cities at the Centre of Illegal Trade in<br />
Drugs, Documentation, Frankfurt a/Main (Germany), 20-22.11.1990.<br />
30 ECAD Declaration for a Drug-free World. Prieiga per internetą:<br />
(http://www.drugnews.nu/article.aspid=4676)<br />
31 Nadelman EA, Cohen P, Drucker E, Locher U, Stimson G, Wodak A. The<br />
Harm Reduction Approach to Drug Control: International Progress.<br />
1994. Prieiga per internetą:http://www.paranoia.cin.drugs/war.<br />
on.drugs/debate/harm-reduction.html.<br />
32 Chand K. Should drugs <strong>be</strong> decriminalised Yes. BMJ 2007;<br />
335(7627):966.<br />
33 Lines R, Elliott R. Injecting drugs into human rights advocacy.<br />
International Journal of Drug Policy 2007;18:453–457.<br />
34 Hunt N. Public health or human rights: What comes first International<br />
Journal of Drug Policy 2004;15(4):231–237.<br />
35 Grossman M, Chaloupka FJ, Shim K. Illegal Drug Use And Public Policy.<br />
Health Affairs 2002; 21 (2):134-145.<br />
36 Smye V, Browne AJ, Varcoe C, Josewski V. Harm reduction, methadone<br />
maintenance treatment and the root causes of health and social<br />
inequities: An intersectional lens in the Canadian context. Harm<br />
Reduct J 2011;8(1):17.<br />
37 Van Amsterdam J, Opperhuizen A, Koeter M, van den Brink W. Ranking<br />
the harm of alcohol, tobacco and illicit drugs for the individual and<br />
the population. Eur Addict Res. 2010;16(4):202-7.<br />
38 Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational<br />
scale to assess the harm of drugs of potential misuse. Lancet 2007;<br />
369: 1047–1053.<br />
39 Anderson P, Chisholm D, Fuhr DC. Effectiveness and cost-effectiveness<br />
of policies and programmes to reduce the harm caused by alcohol.<br />
Lancet 20<strong>09</strong>;373(9682):2234-46.<br />
40 Anderson P, Baum<strong>be</strong>rg B. Alcohol in Europe. London: Institute of<br />
Alcohol Studies; 2006. Prieiga per internetą: http://ec.europa.eu/<br />
health-eu/news_alcoholineurope_en.htm<br />
41 Anderson P, Baum<strong>be</strong>rg B. Alcohol in Europe. London: Institute of<br />
Alcohol Studies. 2006. Prieiga per internetą: http://ec.europa.eu/<br />
health/archive/ph_determinants/life_style/alcohol/documents/<br />
alcohol_europe_en.pdf<br />
42 Waal H. Drug use policies and HIV prevention – unhappy <strong>be</strong>dfellows<br />
In: Waal H. (ed.): Patterns on the European drug scene. An exploratory<br />
of differences. Report based on a COST A6 project. National Institute<br />
for Alcohol and Drug Research, Oslo 1998; 211-8.<br />
43 EMCDDA 2011 m. metinė ataskaita: narkotikų problema Europoje.<br />
Europos Sąjungos leidinių biuras, Liuksemburgas, 2011; 107.<br />
44 EMCDDA. Illicit drug use in the EU: legislative approaches. European<br />
Monitoring Centre for Drugs and Drug Addiction, Lisbon 2005.<br />
45 Amundsen E J, Eskild A, Stigum H, Smith E, Aalen OO. Legal access<br />
to needles and syringes/ needle exchange programmes versus<br />
HIV counselling and testing to prevent transmission of HIV among<br />
intravenous drug users . A comparative study of Denmark, Norway<br />
and Sweden. Eur J Public Health 2003: 13(3): 252-258.<br />
46 Palm J. Moral concerns – Treatment staff and user perspec tives on<br />
63